Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Stock-based compensation | 7,405 | 2,423 |
| Non-cash lease expense | 26 | 8 |
| Accretion/amortization on investments | (493) | — |
| Depreciation expense | 9 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 5,444 | (507) |
| Other assets | — | (60) |
| Accounts payable | 2,328 | 2,677 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's D&A?
- Jade Biosciences (JBIO) reported D&A of $9K in Q1 2026.
- How has Jade Biosciences's D&A changed year-over-year?
- Jade Biosciences's D&A increased by 125.0% year-over-year, from $4K to $9K.
- What is the long-term trend for Jade Biosciences's D&A?
- Over 4 years (2021 to 2025), Jade Biosciences's D&A has grown at a 14.7% compound annual growth rate (CAGR), from $15K to $26K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Jade Biosciences's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude